PSMD1 and COVID-19: Study participants who previously resolved a SARS-CoV-2 infection had significantly higher median anti-S1-RBD-SARS-CoV-2 antibody titers in the respective subgroups with two (median AU/mL [IQR] 13,409 [6934–25,000] vs. 1663 [1094–3060]; p < 0.0001) and three (median AU/mL [IQR]: 24,393 [11,991–25,000] vs. 13,856 [8635–22,705]; p < 0.0001) COVID-19 vaccine doses.